Key result
Next-generation sequencing combined with traditional approaches achieved a confirmed genetic diagnosis in 51% of patients, supporting NGS as a first-line diagnostic tool for congenital muscular dystrophy.
Why the study?
Does next generation sequencing improve diagnostic yield in patients with congenital muscular dystrophy?
Cohort (n=123)
Does next generation sequencing improve diagnostic yield in patients with congenital muscular dystrophy?
Absolute Event Rate: 51% vs 32%
Next-generation sequencing is supported as a first-line tool for genetic evaluation of patients with suspected congenital muscular dystrophy, improving diagnostic yield.
No takes yet. Share an insight, caveat, or question.
NGS may aid undiagnosed CMD cases; leaves open standardization of testing panels before routine adoption.
O’Grady et al. (2016) conducted a cohort in Congenital muscular dystrophy (CMD) (n=123). Next generation sequencing (NGS) combined with traditional approaches vs. Traditional diagnostic approaches was evaluated on Confirmed genetic diagnosis. Next-generation sequencing combined with traditional approaches achieved a confirmed genetic diagnosis in 51% of patients, supporting NGS as a first-line diagnostic tool for congenital muscular dystrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: